Elicera Therapeutics AB (publ), a clinical stage immuno-oncology company, develops cell and gene therapies for immune-based cancer treatments in Sweden. The company's portfolio products in pipeline includes ELC-100 that is in Phase I/IIa clinical trial for neuroendocrine tumors; and ELC-201, which is in preclinical stage for the treatment of various forms of solid cancer. It is also developing ELC-301, a CAR T-cell therapy that is in Phase I/IIa clinical trial for the treatment of Non-Hodgkin's B-cell lymphoma; and ELC-401, a CAR T-cell therapy, which is in preclinical stage for the treatment of brain tumors. Elicera Therapeutics AB (publ) has collaboration with the Vecura R&D division at Karolinska University Hospital and Uppsala University to develop a fully automated production flow of ELC-401 for use in future clinical trials. The company was incorporated in 2014 and is based in Gothenburg, Sweden.
Metrics to compare | ELIC | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipELICPeersSector | |
---|---|---|---|---|
P/E Ratio | −15.0x | −3.1x | −0.5x | |
PEG Ratio | −0.32 | −0.05 | 0.00 | |
Price/Book | 8.6x | 4.0x | 2.6x | |
Price / LTM Sales | 65.3x | 15.0x | 3.2x | |
Upside (Analyst Target) | 13.1% | 20.8% | 43.8% | |
Fair Value Upside | Unlock | 5.1% | 5.1% | Unlock |